Astra-Oxford Vaccine Shows Two Different Efficacy Rates
-
Nov.23 -- A Covid-19 vaccine developed by the University of Oxford and AstraZeneca Plc showed two different outcomes in clinical trials. In one, the vaccine stopped an average of 70% of participants from falling ill. The effectiveness rose to 90% for one of two regimens, using half a dose followed by a full one later, close to the high bar set by Pfizer Inc. and Moderna Inc. Sam Fazeli of Bloomberg Intelligence discusses the findings on "Bloomberg Markets."
Tags:
-
